aTyr Pharma (LIFE) Receiving Somewhat Positive Media Coverage, Report Shows
Headlines about aTyr Pharma (NASDAQ:LIFE) have been trending somewhat positive on Wednesday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. aTyr Pharma earned a news impact score of 0.15 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.1675966560298 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
aTyr Pharma (NASDAQ:LIFE) opened at $3.55 on Wednesday. aTyr Pharma has a twelve month low of $2.10 and a twelve month high of $6.50. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.49 and a current ratio of 9.49.
aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.07. analysts predict that aTyr Pharma will post -1.93 earnings per share for the current year.
LIFE has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, September 7th. ValuEngine downgraded shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Piper Jaffray Companies assumed coverage on shares of aTyr Pharma in a research report on Thursday, September 7th. They set an “overweight” rating and a $7.00 target price for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $4.81.
WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/20/atyr-pharma-life-receiving-somewhat-positive-media-coverage-report-shows.html.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.